Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $1.83 Million - $3.86 Million
901,709 Added 208.27%
1,334,661 $3.02 Million
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $1.32 Million - $2.23 Million
432,952 New
432,952 $1.39 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $161M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Ally Bridge Group (Ny) LLC Portfolio

Follow Ally Bridge Group (Ny) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.